TherapeuticsMD Inc (NASDAQ:TXMD) shot up 6.9% during mid-day trading on Tuesday . The company traded as high as $6.48 and last traded at $6.36. 3,189,117 shares traded hands during trading, an increase of 27% from the average session volume of 2,512,730 shares. The stock had previously closed at $5.95.

A number of research firms have recently issued reports on TXMD. Oppenheimer Holdings, Inc. set a $10.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Thursday, August 17th. CIBC reaffirmed a “market perform” rating and set a $12.00 target price on shares of TherapeuticsMD in a report on Tuesday, May 9th. Deutsche Bank AG began coverage on shares of TherapeuticsMD in a report on Friday, July 21st. They set a “buy” rating and a $10.00 target price for the company. Cowen and Company reaffirmed an “outperform” rating and set a $13.00 target price on shares of TherapeuticsMD in a report on Monday, July 17th. Finally, Jefferies Group LLC set a $15.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, June 14th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $16.14.

The firm’s 50-day moving average is $5.72 and its 200 day moving average is $5.54. The stock’s market cap is $1.30 billion.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $4.25 million during the quarter, compared to analysts’ expectations of $4.91 million. TherapeuticsMD had a negative return on equity of 77.41% and a negative net margin of 462.94%. The firm’s quarterly revenue was down 3.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.11) EPS. Equities analysts expect that TherapeuticsMD Inc will post ($0.44) earnings per share for the current year.

In related news, Director Tommy G. Thompson acquired 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The stock was purchased at an average price of $5.99 per share, for a total transaction of $29,950.00. Following the transaction, the director now owns 3,555 shares in the company, valued at approximately $21,294.45. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Institutional investors have recently bought and sold shares of the stock. Managed Account Services Inc. increased its position in TherapeuticsMD by 5.5% during the 2nd quarter. Managed Account Services Inc. now owns 19,103 shares of the company’s stock worth $101,000 after purchasing an additional 1,000 shares in the last quarter. Amalgamated Bank increased its position in TherapeuticsMD by 7.2% during the 2nd quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock worth $104,000 after purchasing an additional 1,322 shares in the last quarter. Greenwood Capital Associates LLC increased its position in TherapeuticsMD by 17.5% during the 1st quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock worth $146,000 after purchasing an additional 3,022 shares in the last quarter. Principal Financial Group Inc. increased its position in TherapeuticsMD by 3.9% during the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after purchasing an additional 818 shares in the last quarter. Finally, Traynor Capital Management Inc. increased its position in TherapeuticsMD by 14.0% during the 2nd quarter. Traynor Capital Management Inc. now owns 22,799 shares of the company’s stock worth $123,000 after purchasing an additional 2,799 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: “TherapeuticsMD Inc (TXMD) Shares Up 6.9%” was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dailypolitical.com/2017/09/05/therapeuticsmd-inc-txmd-shares-up-6-9.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.